Loading...
XSTO
GENO
Market cap178mUSD
Jun 10, Last price  
26.15SEK
1D
2.75%
1Q
30.75%
Jan 2017
925.49%
IPO
-46.57%
Name

Genovis AB

Chart & Performance

D1W1MN
P/E
52.01
P/S
13.13
EPS
0.50
Div Yield, %
Shrs. gr., 5y
0.74%
Rev. gr., 5y
16.58%
Revenues
130m
-17.62%
379,653986,1781,596,0192,856,0836,080,8738,912,0938,252,06413,268,50118,541,94122,867,26634,567,98060,549,14161,029,72193,017,543102,386,899158,232,000130,358,000
Net income
33m
-46.48%
-27,149,579-17,558,226-11,291,508-13,607,963-19,915,127-15,852,513-22,048,663-19,905,623-15,031,013-7,948,532-1,710,3819,551,5766,445,90224,777,38511,191,00061,500,00032,916,000
CFO
37m
-45.22%
-16,760,756-13,695,153-10,484,825-12,149,160-14,847,903-12,467,813-22,192,335-16,117,301-16,075,111-8,355,087-1,249,59513,125,5533,755,19345,918,901-927,94767,752,00037,116,000

Profile

Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.
IPO date
Nov 11, 2005
Employees
38
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
130,358
-17.62%
158,232
54.54%
102,387
10.07%
Cost of revenue
15,387
15,160
15,018
Unusual Expense (Income)
NOPBT
114,971
143,072
87,369
NOPBT Margin
88.20%
90.42%
85.33%
Operating Taxes
13,413
(6,650)
(3,195)
Tax Rate
11.67%
NOPAT
101,558
149,722
90,564
Net income
32,916
-46.48%
61,500
449.55%
11,191
-54.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
4,513
2,885
Long-term debt
154,129
11,761
Deferred revenue
(2,425)
Other long-term liabilities
71,245
2,425
Net debt
(169,442)
35,381
(58,273)
Cash flow
Cash from operating activities
37,116
67,752
(928)
CAPEX
(10,440)
(3,825)
Cash from investing activities
14,422
(12,808)
(3,825)
Cash from financing activities
(5,357)
(4,513)
(3,732)
FCF
116,166
70,231
70,337
Balance
Cash
169,442
123,261
72,830
Long term investments
89
Excess cash
162,924
115,349
67,800
Stockholders' equity
(24,845)
(88,981)
Invested Capital
299,217
294,976
221,957
ROIC
34.18%
57.93%
41.35%
ROCE
38.42%
52.57%
64.53%
EV
Common stock shares outstanding
65,466
65,466
65,466
Price
24.70
-52.50%
52.00
13.17%
45.95
-37.05%
Market cap
1,617,003
-52.50%
3,404,217
13.17%
3,008,150
-37.05%
EV
1,447,561
3,439,598
2,950,898
EBITDA
114,971
152,794
94,000
EV/EBITDA
12.59
22.51
31.39
Interest
2,264
14,495
Interest/NOPBT
1.58%
16.59%